In the recent Rare Oncology Agnostic Research basket trial, the rate of responses to the combination of BRAF/MEK inhibition obtained in high-grade as well as in low-grade glioma cohorts has been encouraging (49), thus advocating BRAF testing in clinical practice (50, 51). The gene discussed is BRAF; the disease is central nervous system cancer.